Pharmacokinetic analysis of anti-hemophilic factor in the obese patient

Haemophilia

Volumn 20, Issue 2, 2014, Pages 226-229

  Graham, A ^a   Jaworski, K ^a  

^a Hemophilia Center of Western Pennsylvania   (United States)

Author keywords

Hemophilia; Ideal body weight; Obesity; Pharmacokinetics; Recombinant factor VIII

Indexed keywords

HEMOPHILIA; IDEAL BODY WEIGHT; OBESITY; PHARMACOKINETICS; RECOMBINANT FACTOR VIII;

ADULT; BODY MASS INDEX; BODY WEIGHT; DRUG COSTS; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84894229740     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12300     Document Type: Article

References (13)

1. Obesity and overweight for professionals: data and statistics: U.S. Obesity Trends. Atlanta GA: Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/obesity/data/trends.html (Accessed August 25, 2013).
2. Ingram GI. Calculating the dose of factor VIII in the management of haemophilia. Br J Haematol 1981; 48: 351-4.
3. Komwilaisak P, Blanchette V. Pharmacokinetic studies of coagulation factors: relevance of plasma and extracellular volume and body weight. Haemophilia 2006; 12(Suppl. 4): 33-9.
4. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
5. Meyhoff CS, Lund J, Jenstrup MT et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109: 787-92.
6. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505-8.
7. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokine-tics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
8. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; on behalf of the International Prophylaxis Study Group (ISPG) Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
9. Tuinenburg A, Biere-Rafi S, Peters M et al. Obesity in haemophilia patients: effects on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. Haemophilia 2013; 19: 744-52.
10. Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica 2013; 98: 1481-6. doi: 1-/3324/haematol.2043.084038.
11. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother 2000; 34: 1066-9.
12. Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 2010; 16(Suppl. 3): 7-12.
13. Levitt DG, Heymsfield SB, Pierson R, Shapses S, Kral JG. Physiological modes of body composition and human obesity. Nutr Metab 2007; 4: 19.